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OBJECTIVE—The objective of this study was to characterize
the changes in brain metabolism caused by antecedent recurrent
hypoglycemia under euglycemic and hypoglycemic conditions in
a rat model and to test the hypothesis that recurrent hypoglyce-
mia changes the brain’s capacity to utilize different energy
substrates.
RESEARCH DESIGN AND METHODS—Rats exposed to re-
current insulin-induced hypoglycemia for 3 days (3dRH rats) and
untreated controls were subject to the following protocols:
[2-
13C]acetate infusion under euglycemic conditions (n  8),
[1-
13C]glucose and unlabeled acetate coinfusion under euglyce-
mic conditions (n  8), and [2-
13C]acetate infusion during a
hyperinsulinemic-hypoglycemic clamp (n  8). In vivo nuclear
magnetic resonance spectroscopy was used to monitor the rise
of
13C-labeling in brain metabolites for the calculation of brain
metabolic ﬂuxes using a neuron-astrocyte model.
RESULTS—At euglycemia, antecedent recurrent hypoglycemia
increased whole-brain glucose metabolism by 43  4% (P  0.01
vs. controls), largely due to higher glucose utilization in neurons.
Although acetate metabolism remained the same, control and
3dRH animals showed a distinctly different response to acute
hypoglycemia: controls decreased pyruvate dehydrogenase
(PDH) ﬂux in astrocytes by 64  20% (P  0.01), whereas it
increased by 37  3% in neurons (P  0.01). The 3dRH animals
decreased PDH ﬂux in both compartments (75  20% in
astrocytes, P  0.001, and 36  4% in neurons, P  0.005).
Thus, acute hypoglycemia reduced total brain tricarboxylic acid
cycle activity in 3dRH animals (37  4%, P  0.001), but not in
controls.
CONCLUSIONS—Our ﬁndings suggest that after antecedent
hypoglycemia, glucose utilization is increased at euglycemia and
decreased after acute hypoglycemia, which was not the case in
controls. These ﬁndings may help to identify better methods of
preserving brain function and reducing injury during acute
hypoglycemia. Diabetes 58:1266–1274, 2009
L
arge clinical trials have established that the long-
term complications of diabetes can be mitigated
by tight glycemic control (1,2). Intensive insulin
therapy, however, is limited by an increased risk
of severe hypoglycemia, which results, in large part, from
a blunting of counterregulatory responses as well as
reduced awareness of hypoglycemia (3–6). Characteriza-
tion of the underlying metabolic adaptations involved
could lead to new therapeutic approaches aimed at im-
proving glycemic control without compromising the risk
of severe hypoglycemia.
Impaired judgment and decreased memory function
during acute hypoglycemia are thought to be conse-
quences of alterations of brain energy metabolism, in
particular the absence of glucose, the primary energy
substrate for the brain (7,8). The blunting of epinephrine
and glucagon responses to hypoglycemia observed in type
1 diabetic patients exposed to frequent hypoglycemic
episodes are reproduced in animal models of recurrent
antecedent insulin-induced hypoglycemia, suggesting that
such models may offer insights into the metabolic adapta-
tions observed in the clinical setting (9–11). Studies of
cognitive performance using a spatial memory task in
nondiabetic and diabetic rats exposed to recurrent hypo-
glycemia for 3 consecutive days (3dRH rats) and in non-
diabetic animals exposed to weekly bouts of hypoglycemia
for nearly a year have revealed better performance at
euglycemia, suggesting that adaptations of brain glucose
transport and/or metabolism are similar to those reported
for diabetic patients (9,10). These studies suggest that our
animal models may offer insights into the metabolic adap-
tations observed in the clinical setting (9,11,12).
It is also possible that when the brain is repeatedly
deprived of its main energy substrate, glucose, its capacity
to take up and utilize alternate fuels such as monocarboxy-
lic acids or ketone bodies is increased. This view is
supported by a recent nuclear magnetic resonance (NMR)
spectroscopy study that demonstrated an increase in
acetate metabolism in type 1 diabetic patients with hypo-
glycemia unawareness (13). In contrast, 3dRH rodents
under hypoglycemic conditions performed worse on a
memory task than saline-injected controls (9).
The current study was undertaken to assess the effects
of antecedent recurrent hypoglycemia on the brain’s ca-
pacity to oxidize glucose and an alternate fuel (acetate).
Three different experiments were conducted using both
control and 3dRH animals. First, we measured neuronal
and astroglial metabolic ﬂuxes under euglycemic condi-
tions using [2-
13C]acetate, which is primarily metabolized
by astroglia-labeling neurons through the glutamate/glu-
tamine neurotransmitter cycle. The accumulation of label
in the stable metabolite pools of glutamine and glutamate
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1H-observed,
13C-edited (
1H-
[
13C]) NMR spectroscopy. This approach, when used in
conjunction with a two-compartment mathematical model
of brain metabolism (Fig. 1), allows the quantitation of the
rates of neuronal and glial tricarboxylic acid (TCA) cycles,
glutamate/glutamine neurotransmitter cycle, and other
metabolic pathways in brain (13,14). Second, to more
directly assess neuronal metabolism using a substrate that
is predominately metabolized in neurons, we measured
metabolic ﬂuxes during infusion of [1-
13C]glucose in con-
junction with unlabeled acetate. Lastly, metabolic ﬂuxes
were assessed during acute hypoglycemic-hyperinsuline-
mic clamp and [2-
13C]acetate infusion to reveal the extent
to which glucose and acetate contributes to brain oxida-
tive metabolism when blood glucose is deﬁcient.
RESEARCH DESIGN AND METHODS
Male Sprague-Dawley rats (Charles River, Wilmington, MA) of 220–250 g were
housed in the Yale Animal Resource Center, fed a standard pellet diet (ProLab
3000; Agway, Syracuse, NY), and maintained on a 12-h day/night cycle.
Experimental protocols were in accordance with laboratory animal care
guidelines and were approved by the Yale animal care and use committee.
Recurrent hypoglycemia. Recurrent hypoglycemia was induced as previ-
ously described (15). Brieﬂy, animals received intraperitoneal injections
of regular insulin (10 U/kg Humulin R; Lilly, Indianapolis, IN) to produce 3 h
of hypoglycemia on 3 consecutive days, resulting in tail vein glucose levels of
30–40 mg/dl. After 3 h, animals were given access to food and allowed to
return to euglycemia. On the following day, NMR experiments were
performed.
Surgical preparation. During surgical preparation for in vivo NMR experi-
ments, animals were anesthetized with 3% halothane, underwent tracheotomy,
and were ventilated with a mixture of 30% O2/69% N2O/1% halothane via a
small-animal ventilation system (Harvard Apparatus, Holliston, MA). The left
femoral artery was catheterized for continuous monitoring of blood pressure,
plasma sampling, and blood gas analysis (Table 1). Core body temperature
was measured and maintained at 37  1°C using a water heating pad. Both
femoral veins were cannulated for infusion of insulin, glucose, and acetate.
Isotopically labeled substrates were infused into a separate line using com-
puter-controlled pumps (Harvard Apparatus). Animals were then placed into
a plastic holder with a surface coil positioned directly on top of the scalp for
NMR experiments.
Experimental groups
Euglycemia: acetate infusion. For this study, 2 mol/l [2-
13C]acetate (99%
13C-sodium salt; Cambridge Isotopes, Andover, MA) at pH  7 was infused
into 3dRH (n  8) and control (n  8) animals under basal euglycemic
conditions. Animals had free access to food the night before the experiment
to avoid signiﬁcant ketone body accumulation. A bolus continuous infusion of
labeled acetate designed to produce steady-state plasma levels was given
according to the following protocol: 6.25 mol  min
1  g
1 f r o m0t o1 5s ,
0.875 from 15 s to 4 min, 0.5 from 4 to 8 min, and 0.25 thereafter.
Euglycemia: glucose/acetate coinfusion. Because of the uncertainty
associated with this method of determining neuronal PDH ﬂux (VpdhN), we
performed a coinfusion study with [1-
13C]glucose and unlabeled acetate to
measure VpdhN more directly. For this study, 1.1 mol/l [1-
13C]glucose (99%
13C;
Cambridge Isotopes, Andover, MA) was coinfused with 2 mol/l acetate into
3dRH (n  8) and control (n  8) animals under basal euglycemic conditions.
Unlabeled acetate was infused in identical doses as in the protocol described
above, and 20 min later [1-
13C]glucose was administered as a bolus of 4.05
mol  g
1  min
1 for 15 s followed by stepped exponential reduction of
infusion rates every 30 s for the next 8 min, arriving at a steady rate of 0.051
mol  g
1  min
1 for the remainder of the experiment. Regular insulin (50
mU  kg
1  min
1) was used during the initial 30 min to prevent plasma
glucose from increasing in association with the labeled glucose infusion.
Hypoglycemia: acetate infusion. For this study, 2 mol/l [2-
13C]acetate was
infused into 3dRH (n  8) and control (n  8) animals during acute
insulin-induced hypoglycemia. Animals were fasted overnight before a hyper-
insulinemic-hypoglycemic clamp study (50 mU  kg
1  min
1) in which a
variable infusion of 20% dextrose (Hospira, Lakeforest, IL) was used to
maintain plasma glucose at the target level of 2.1  0.2 mmol/l (Fig. 2A).
Plasma glucose concentrations (Fig. 2B) were measured every 10 min in
between NMR scans using a Beckman glucose analyzer 2 (Beckman Coulter,
Fullerton, CA). Infusion rates of labeled acetate were reduced by 20%
compared with the euglycemic studies to optimize physiological parameters,
such as blood pressure, blood pH, PO2, and PCO2. This dose, however, was
sufﬁcient for plasma acetate levels to saturate transport.
NMR spectroscopy. After placement of the animals into the scanner, in vivo
NMR spectroscopy was performed during the respective infusions in a 9.4 T
horizontal bore magnet (Magnex; Scientiﬁc, Oxford, U.K.) equipped with a
9-cm-diameter gradient coil insert (490 mT/m, 175 S; Resonance Research,
Billerica, MA). The magnet was interfaced to an Avance console (Bruker,
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FIG. 1. Two-compartment model of the contribution of infused labeled acetate ([2-
13C]Ac) to astroglial and neuronal metabolism. Modiﬁed after
Lebon et al. (33). Ac-CoA, acetyl-CoA; Gln, glutamine; Glu, glutamate; -KG, -ketoglutarate; Lac, lactate; OAA, oxaloacetate; Pyr, pyruvate.
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DIABETES, VOL. 58, JUNE 2009 1267Billerica, MA). Spectra were obtained from a 14-mm-diameter surface radio-
frequency coil tuned to
1H (400 MHz).
13C-inversion and decoupling radiofre-
quency pulses (100 MHz) were delivered by two orthogonally positioned coils
driven in quadrature. Localized
1H-[
13C] NMR spectra were obtained from a
volume of 180 l( 6 5  6m m
3), centered in the middle of the cortex. Field
homogeneity was optimized by adjustment of ﬁrst- and second-order shims
using the automated Fastmap algorithm (16), achieving a line-width-at-half-
height of 15 Hz. Localization was achieved with the LASER (localized by
adiabatic selective refocusing) pulse sequence and water suppression by
CHESS 4 (chemical shift selective 4) imaging (17–19). Spectra were collected
with repetition at a time of 2.5 s (20). At the end of the experiment, animals
were removed from the magnet, and brains were frozen in situ using liquid
nitrogen while mechanical ventilation was continued to preserve labile
metabolites (21,22).
Brain extracts and plasma samples for high-resolution NMR spectroscopy
were prepared using a procedure described previously (23,24). Metabolite
concentrations and
13C-enrichments were measured using
1H-[
13C] NMR at
11.7 T on a Bruker Avance vertical bore spectrometer.
Metabolic modeling. Metabolic ﬂuxes were determined by ﬁtting the two-
compartment model of astrocytic and neuronal metabolism depicted in Fig. 1,
which is based on the time courses of
13C-enrichment of the C4 position of
glutamate and glutamine (Glu4 and Gln4) during the infusion of [2-
13C]acetate
(Fig. 3A) and the
13C-enrichment of Glu3 and Gln3 at the end of infusion (Fig.
3B). For a driver function, the measured time course of [2-
13C]acetate in the
brain was used instead of plasma acetate levels to eliminate uncertainties
associated with acetate transport kinetics. Mass and isotopic ﬂows from
[2-
13C]acetate to glial and neuronal glutamate and glutamine pools were
expressed as coupled differential equations (see the supplementary materials,
available in an online appendix at http://diabetes.diabetesjournals.org/cgi/
content/full/db08-1664/DC1) within the CWave 3.0 software package (25)
running in Matlab 7.0 (Mathworks, Natick, MA). The equations were solved
using a ﬁrst-order Runge-Kutta algorithm, and ﬁtting optimization was
achieved using simulated annealing hybridized with a Levenberg-Marquardt
algorithm (26) with ﬁxed values for Vcyc/VtcaN and VkbN, where Vcyc indicates
the rate of the glutamate/glutamine neurotransmitter cycle, VtcaN indicates the
rate of neuronal tricarboxylic acid cycle, and VkbN indicates the rate of
neuronal -hydroxybutyrate utilization. The Vcyc/VtcaN ratio was calculated
from the steady-state
13C percentage enrichments of Glu4 and Gln4 from
[2-
13C]acetate according to the following (24):
Vcyc/VtcaN  (Glu4N  ci)/(Gln4A  Glu4N)
where “N” and “A” designate the neuronal and astroglial compartments,
respectively. We assumed that glutamate was distributed between neurons
(90%) and astroglia (10%) and glutamine was located entirely in astroglia. The
steady-state enrichment of astroglial Glu4 was assumed to equal that of Gln4;
thus, the percentage enrichment of neuronal glutamate is given by Glu4N 
(Glu4 – Gln4  0.1)/0.9. The correction factor ci removes contributions to
Glu4N (at the level of acetyl-CoA) from metabolism of
13C-labeled plasma
products derived from [2-
13C]acetate metabolism in peripheral tissues, e.g.,
plasma glucose-C1 (and/or lactate-C3) and -hydroxybutyrate (BHB)-C4/C2
TABLE 1
Effect of 2-
13C	acetate infusions on physiological variables and substrates (concentrations and
13C-enrichments) measured in arterial
plasma of control and 3dRH rats under euglycemic and hypoglycemic conditions
Euglycemia Hypoglycemia
Control 3dRH Control 3dRH
Before After Before After Before After Before After
pH 7.37  0.02 7.40  0.03 7.36  0.01 7.35  0.02 7.38  0.01 7.43  0.01 7.40  0.01 7.47  0.02*†
PCO2 (mmHg) 38  14 5  24 1  44 4  43 5  33 8  23 5  33 7  4
PO2 (mmHg) 130  7 120  5 148  5 147  9 130  10 170  15 130  10 160  15
Glucose
mmol/l 9.4  0.7 12.5  1.1 8.1  0.03 11  0.3 2.3  0.2 2.0  0.2 2.3  0.7 2.3  0.7
%E 0 n.d. 0 n.d. 0 n.d. 0 n.d.
BHB
mmol/l 0.3  0.03 0.5  0.1 0.3  0.03 0.37  0.07 1.2  0.07 0.9  0.06 1.2  0.6 0.7  0.4
%E 0 18  0.7 0 17  5 0 17.9  1.3 0 3.3  1.9
Lactate
mmol/l 1.3  0.1 1.6  0.3 1.0  0.07 1.20  0.02 1.0  0.07 0.8  0.07 1.0  0.2 0.8  0.4
%E 0 2.6  0.4 0 2.5  0.7 0 n.d. 0 n.d.
Acetate
mmol/l 0.13  0.01 9.6  0.9 0.14  0.02 10.6  1.5 0.13  0.02 8.2  2 0.14 11  5
%E 0 90  0.7 0 88  1.3 0 86  20 8 4  6
The natural abundance of
13C (1.1%) was subtracted from the percentage enrichments (%E). *P  0.05 and P  0.01 for control vs. 3dRH;
†P  0.05 and P  0.01 for euglycemia vs. hypoglycemia. n.d., non-detectable.
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FIG. 2. Hypoglycemic-hyperinsulinemic clamp. A: Plasma glucose con-
centration. B: Glucose infusion rate (GIR). The time point at t  0 min
indicates the beginning of the
13C-labeled acetate infusion and spectral
acquisition. Error bars  SE. , controls; , 3dRH.
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materials).
Statistical analysis. The error distributions were reported as the SE. P
values were calculated using Student’s t test using Microsoft Excel, and
P  0.05 was considered to be statistically signiﬁcant. Monte-Carlo
analysis of each animal’s dataset was performed with CWave to assess the
distribution of uncertainties in the model parameters for individual ani-
mals (27) (see supplemental materials). The uncertainties in Monte Carlo
ﬁtting were smaller than the group variabilities for each parameter
reported in this study, indicating that treatment differences were not
obscured by uncertainties associated with data ﬁtting.
RESULTS
Effect of recurrent hypoglycemia on acetate metabo-
lism under euglycemia. Within 1 min of initiating the
[2-
13C]acetate infusion, a steady-state plasma level of 
10
mmol/l was reached and maintained throughout the 100-
min experiment. There was rapid
13C-labeling of plasma
BHB at the C4 position (reaching 
18%) and at the C3
position of plasma lactate (
2.5%) in both control as well
as 3dRH pretreated animals. A 30% increase in blood
glucose concentration occurred in both groups during the
acetate infusion, without any detectable
13C-labeling of
glucose (Table 1). Brain [2-
13C]acetate accumulation in the
in vivo NMR spectra was immediately observed, suggest-
ing that metabolic ﬂux would not be limited by blood-brain
barrier transport of acetate in either group (Table 2).
Although animals from both groups showed similar
plasma glucose levels, exposure to antecedent recurrent
hypoglycemia resulted in 34% higher brain glucose con-
centrations (1.27  0.04 and 1.72  0.08 mol/g for control
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40’
90’
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Gln4 Glu4
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Gln3
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B
FIG. 3. NMR spectra. A: Representative stack of in vivo
1H-[
13C] difference spectra acquired over time, revealing gradual accumulation of brain
[2-
13C]acetate and its subsequent appearance in the stable metabolite pools of Glu4, Glu3, Gln4, and Gln3. B: Representative high-resolution
1H-[
13C] spectra of brain tissue extracts used to further resolve the metabolite concentrations and enrichments of different carbon positions of
glutamate-C4,3,2 (Glu4,3,2); glutamine-C4,3,2 (Gln4,3,2); GABA-C2,3,4, aspartate-C3 (Asp3); alanine-C3 (Ala3); and lactate-C3 (Lac3). Combina-
tion of these two measurements revealed the time courses of label accumulation in these metabolite pools, which were then used in the
two-compartment model of brain metabolism to determine the metabolic ﬂuxes. Cr, creatine; NAA, N-acetylaspartate; PCr, phosphocreatine.
L. JIANG AND ASSOCIATES
DIABETES, VOL. 58, JUNE 2009 1269and 3dRH, respectively; P  0.002), suggesting an in-
creased glucose transport capacity in the 3dRH group.
The Vcyc/VtcaN ratio, representing the coupling between
glutamate/glutamine cycling and the neuronal TCA cycle,
had no signiﬁcant change after exposure to recurrent
hypoglycemia (0.58  0.05) in comparison to controls
(0.51  0.03, P  0.15). Figure 4 (top panels) shows the
group averages for
13C time courses of Glu4 and Gln4
TABLE 2
Brain extract metabolite concentrations (mol/g) and
13C-percentage enrichments (%E) at the end of the 2-
13C	acetate infusion
Euglycemia Hypoglycemia
Control 3dRH Control 3dRH
Acetate
Concentration (mol/g) 1.5  0.2 1.2  0.3 1.2  0.1 0.8  0.2
C2 (%E) 90  0.7 88  1.4 86  28 4  2
Glucose
Concentration (mol/g) 1.27  0.04 1.72  0.08* 0.35  0.04 0.4  0.04
C1 (%E) n.d. n.d. n.d. n.d.
Lactate
Concentration (mol/g) 2.2  0.2 2.3  0.2 1.9  0.5 3.4  0.3*†
C3 (%E) 2.3  0.2 2.6  0.2 3.4  0.5 1.2  0.4*†
Aspartate
Concentration (mol/g) 2.9  0.1 2.7  0.1 3.3  0.5 3.9  0.5*†
C3 (%E) 7.1  0.8 6.5  0.6 5.9  0.4 6.5  0.8
Glutamate
Concentration (mol/g) 10.8  0.5 11.5  0.6 11.5  0.6 12.1  0.8
C2 (%E) 2.8  0.3 3.2  0.3
C3 (%E) 7.7  0.4 7.6  0.5 8.7  0.6 7.7  0.7
C4 (%E) 10.5  0.3 10.8  0.5 13.9  0.6† 14.3  1‡
Glutamine
Concentration (mol/g) 6.9  0.3 6.6  0.3 7.2  0.4 7.2  0.6
C2 (%E) 7.3  0.4 6.7  0.3
C3 (%E) 11.2  0.7 10.4  0.2 11.5  0.4 10.0  0.6
C4 (%E) 23.7  1.0 22.9  0.8 27.8  0.5† 29  0.8†
GABA
Concentration (mol/g) 1.6  0.1 1.7  0.2 1.8  0.2 2.7  0.4‡
C2 (%E) 9.2  0.4 10.3  0.5 12.0  0.3‡ 11.3  1
C3 (%E) 5.3  0.7 5.9  0.4 7.3  0.6 5.3  1.4
C4 (%E) 6.9  0.7 6.1  0.3 9.2  1.1† 7.3  1.2
The natural abundance of
13C (1.1%) was subtracted from the percentage enrichments. *P  0.05 3dRH vs. control; †P  0.05; ‡P  0.01
hypoglycemia vs. euglycemia within a group. n.d., non-detectable.
0
5
10
15
20
25
30
35
Time (min)
0
5
10
15
20
25
30
35
0 2 04 06 08 0 1 0 0 0 2 04 06 08 0 1 0 0 0 2 04 06 08 0 1 0 0
1
3
C
 
E
n
r
i
c
h
m
e
n
t
 
(
%
)
1
3
C
 
E
n
r
i
c
h
m
e
n
t
 
(
%
)
1
3
C
 
E
n
r
i
c
h
m
e
n
t
 
(
%
)
1
3
C
 
E
n
r
i
c
h
m
e
n
t
 
(
%
)
1
3
C
 
E
n
r
i
c
h
m
e
n
t
 
(
%
)
Time (min)
A B C
0
5
10
15
20
25
30
35
Time (min)
0
5
10
15
20
25
30
35
0 2 04 06 08 0 1 0 0
Time (min)
0
5
10
15
20
25
30
35
0 2 04 06 08 0 1 0 0
Time (min)
1
3
C
 
E
n
r
i
c
h
m
e
n
t
 
(
%
)
0
5
10
15
20
25
30
35
0 2 04 06 08 0 1 0 0
Time (min)
FIG. 4. Time courses of Glu4 and Gln4 labeling during labeled substrate infusions. A: [2-
13C]acetate at euglycemia. B: [1-
13C]glucose and unlabeled
acetate at euglycemia. C: [2-
13C]acetate at hypoglycemia. Group-averaged data are depicted in the upper panels, whereas representative
individual animals with best ﬁts of the two-compartment metabolic model appear in lower panels. , Gln4 control; , Gln4 3dRH; f, Glu4 control;
, Glu4 3dRH. Error bars  SE.
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13C]acetate infusion in control and 3dRH animals
under euglycemia. Individual time courses served as the
input for the metabolic model.
Although brain acetate metabolism (cerebral metabolic
rate [CMR]ac) did not differ signiﬁcantly between 3dRH
and control animals (0.15  0.01 vs. 0.16  0.01 mol  g
1
 min
1 for control vs. 3dRH, P  0.2), brain glucose
metabolism (CMRgl) under euglycemia was increased in
the 3dRH animals by 43  4% (0.46  0.3 vs. 0.66  0.5
mol  g
1  min
1 for control vs. 3dRH, P  0.003) (Fig.
5A). This increase was further reﬂected by a 50% increase
of VpdhN in the neuronal compartment (0.70  0.08 vs.
1.06  0.09 mol  g
1  min
1, P  0.008), suggesting an
overall increased capacity to utilize glucose. Total brain
TCA cycle activity increased as a consequence (1.03  0.05
vs. 1.45  0.07 mol  g
1  min
1, P  0.004). Because the
metabolism of labeled acetate does not result in
13C label
ﬂow through pyruvate dehydrogenase, VpdhN is instead
calculated by the metabolic model based on several dilu-
tional ﬂuxes, with the main contribution coming from
unlabeled glucose.
Effect of recurrent hypoglycemia on neuronal PDH
ﬂux under euglycemia. The plasma glucose level during
the coinfusion of [1-
13C]glucose and unlabeled acetate was
maintained at 9  1 mmol/l in the control and 8.1  0.8
mmol/l in the 3dRH group (P  0.11). Throughout, acetate
concentrations were comparable between the groups as
well as in comparison to the labeled acetate infusions,
described above. In contrast, we did not observe labeling
of BHB, but we did see a signiﬁcantly higher degree of
[3-
13C]lactate labeling in the plasma (9.5  0.4 vs. 6.4 
0.06% fE for control vs. 3dRH, P  0.02).
The rate of isotopic enrichment of the brain glutamate
pool was considerably higher than that of glutamine (Fig.
4), a reﬂection of the metabolic compartmentalization and
the higher contribution of glucose-derived metabolites to
neuronal metabolism. Because lactate uses the same met-
abolic pathway as glucose in the brain, it equally contrib-
utes to VpdhN. The two-compartment model, using the
13C
time courses of plasma glucose and lactate as well as brain
Glu4 and Gln4, was therefore used to calculate VpdhN.
Comparing results from the [2-
13C]acetate infusion with
this direct determination of VpdhN using [1-
13C]glucose
revealed essentially the same values (0.75  0.05 and
1.09  0.07 mol  min
1  g
1 for control and 3dRH,
respectively; P  0.003) (Fig. 5A), thereby conﬁrming our
ﬁnding of increased VpdhN in the 3dRH group.
Effect of recurrent hypoglycemia on astrocytic and
neuronal metabolism during acute hypoglycemia. In
this experiment the hyperinsulinemic-hypoglycemic clamp
Control (euglycemia)
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FIG. 5. Metabolic ﬂuxes derived from two-compartment model. A: In control and 3DRH animals under euglycemia and hypoglycemia. B:
Percentage change in metabolic rates from euglycemia (eu) to hypoglycemia (hypo) within groups, calculated as: [(euglycemia – hypoglycemia)/
euglycemia]  100.
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mmol/l in both groups during the infusion of [2-
13C]acetate
(Fig. 2). In keeping with a loss of counterregulatory
responses in the 3dRH model, a 20% higher glucose
infusion rate was required in these animals to maintain the
same degree of glycemia. The other physiological param-
eters were controlled at similar levels, and plasma concen-
trations of acetate, lactate, and BHB were comparable
between groups (Table 1). The most striking change was a
decrease in BHB labeling from 17.9  3.9 to 3.3  1.9%
(P  0.001) after exposure to recurrent hypoglycemia
(Table 2), consistent with the presence of reduced periph-
eral ketones in the context of increased peripheral acetate
utilization. Furthermore, during hypoglycemia, brain con-
centrations of GABA in 3dRH rats were increased by 50%
(P  0.05) compared with controls, without signiﬁcant
changes of
13C-enrichment of GABA. When comparing the
time courses of Glu4 and Gln4 for the 3dRH and control
groups, we observed no obvious differences in the rates of
Gln4 labeling and only small changes in Glu4 labeling (Fig.
4C).
We constrained two parameters in ﬁtting the metabolic
model to the time course data: the ratio of glutamate
neurotransmitter cycling to neuronal TCA cycle ﬂux (Vcyc/
VtcaN) and the rate of neuronal ketone body utilization
(VkbN). In the current study, blood BHB enrichment was
17.9 and 3.3% at the end of the [2-
13C]acetate infusion in
hypoglycemic control and 3dRH animals, respectively,
which led to relatively small contributions (and correc-
tions in Eq. 1) (supplementary materials) of 2.1% ( 100 
0.179  0.12) and 0.2% ( 100  0.033  0.12). Including
these corrections in Eq. 1 had only minor and insigniﬁcant
(P  0.17) effects on the calculated values of Vcyc/VtcaN for
the control (0.52  0.07) and 3dRH (0.64  0.09) animals.
VkbN was set to 0.04  0.02 (3dRH) and 0.04  0.01
(control) based on individual plasma BHB concentrations.
Together with the brain [2-
13C]acetate concentration,
the time courses of label appearance in
13C brain acetate,
plasma BHB, brain Glu4, Gln4, and end points of Glu3 and
Gln3, we determined the metabolic ﬂuxes of 3dRH versus
control animals under hypoglycemic clamp conditions
(Fig. 5B). Although we observed a 24  5% lower VpdhN in
3dRH animals compared with controls (P  0.004) and a
decrease in total TCA cycle ﬂux (1.12  0.02 vs. 0.91  0.08
mol  min
1  g
1, P  0.007), the other parameters
remained similar between the groups (CMRac P  0.2, Vgln
P  0.3, VpdhA P  0.4, and Vcyc P  0.2).
Comparing metabolic ﬂuxes of control animals under
euglycemic and hypoglycemic conditions, we found no
signiﬁcant changes in overall brain acetate metabolism
(CMRac, P  0.5). In controls, brain glucose consumption
(CMRgl) in response to hypoglycemia was increased by
16  1% (P  0.05), mostly due to an increase in glucose-
related ﬂuxes in the neuronal compartment, namely VpdhN
(37  3%, P  0.01) and VtcaN (40  3%, P  0.05). In
contrast, astroglial glucose uptake (VpdhA) was decreased
by 32  5% (P  0.01), suggesting a redistribution of
glucose consumption to maintain neuronal function, as
reﬂected by a preserved brain total TCA cycle activity (Fig.
5B).
Similar to controls, 3dRH animals showed no changes in
CMRac. However, in a response opposite to controls, a
signiﬁcant 40  5% decrease in CMRgl (P  0.001) was
observed in response to hypoglycemia (Fig. 5B). Glucose
ﬂux in the astrocytic compartment dropped by 75  20%
(VpdhA, P  0.001) and in neurons by 36  4% (VpdhN, P 
0.005). The combined effect of these decreases in both
compartments is a resultant total brain TCA cycle activity
decrease by 37  4% (P  0.001). Comparing the relative
contributions of acetate and glucose when going from
euglycemia to hypoglycemia (CMRac/CMRgl), the control
group showed a 12% decrease (P  0.06), whereas 3dRH
rats revealed a 24% increase (P  0.006), indicating an
increased relative contribution of acetate to brain metab-
olism in 3dRH animals under hypoglycemic conditions. In
this context, however, it is important to note that at
baseline euglycemic conditions, 3dRH animals already
show a 43% higher degree of brain glucose consumption
(CMRgl) than control animals (P  0.004).
DISCUSSION
In this study, we measured the rates at which glucose and
an alternate fuel (acetate) is oxidized under different
glycemic conditions. Measurements of brain metabolism
in animals exposed to recurrent hypoglycemia resulted in
two main observations. First, after antecedent recurrent
hypoglycemia, basal brain glucose metabolism at euglyce-
mia is increased in comparison to controls. This increase
was mainly attributable to higher neuronal glucose oxida-
tion, suggesting that when glucose is present in sufﬁcient
amounts, neurons are better able to use glucose. Second,
under standardized relatively severe hypoglycemic con-
ditions, 3dRH animals showed a decrease in brain
glucose consumption in neurons and astroglia, which
contrasts with control animals, in which neuronal glu-
cose metabolism was preserved (Fig. 5A). Thus, there is
a fundamentally different metabolic response of neu-
rons to hypoglycemia between 3dRH and control ani-
mals: whereas acetate consumption remained comparable
under euglycemia and hypoglycemia in both groups, ace-
tate comprised a greater relative contribution to total
brain oxidation.
Controversy exists regarding the relative degree of
cognitive impairment caused by acute hypoglycemia in
patients with type 1 diabetes compared with nondiabetic
subjects (rev. in 28). This may be in part a consequence of
metabolic adaptations that occur in response to different
degrees of antecedent exposure to hypoglycemia (29,30).
In a previous study using the same rodent model, 3dRH
animals subjected to a spatial memory test under euglyce-
mia performed better than controls, whereas they did
worse during acute hypoglycemia (9). The current obser-
vation of higher total TCA cycle activity under euglycemia
and lower activity under hypoglycemia in 3dRH animals
parallels this biological effect. The better performance
under euglycemia in 3dRH animals may be related, in part,
to changes in glucose transport across the blood-brain
barrier, resulting in a higher brain glucose level at compa-
rable plasma glucose, an effect we also observed using
microdialysis in previous studies of our 3dRH model
(9,15). The 34% increase in brain glucose levels measured
here in the 3dRH group at euglycemia is consistent with
the 17% increase reported in type 1 diabetic patients with
hypoglycemia unawareness at euglycemia (10). Further-
more, our data establish that the higher brain glucose
concentration is not the consequence of a decrease in
glucose utilization, but instead occurs despite accelerated
brain glucose metabolism.
To overcome the relative uncertainty associated with
using [2-
13C]acetate, a predominantly glial fuel, for the
calculation of glucose consumption, we performed a con-
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13C]glucose as a substrate.
The measured neuronal PDH ﬂux in 3dRH animals (1.06 
0.10 vs. 1.09  0.07 mol  min
1  g
1 for [2-
13C]acetate vs.
[1-
13C]glucose) was the same for both substrates, further
supporting the accuracy of our metabolic model.
In this animal study, transporter kinetics were saturated
by an infusion of [2-
13C]acetate at a level higher than is
ethically and technically permissible in comparable human
studies. The acetate infusion resulted in reliable brain
acetate measurements, which then allowed us to accu-
rately determine metabolic ﬂuxes independent of potential
changes in monocarboxylic acid transport transporter
activity at the blood-brain barrier, which are anticipated in
the context of exposure to recurrent hypoglycemia (13).
In the current study, all animal groups (euglycemic and
hypoglycemic) showed
13C-labeling of BHB from [2-
13C]ac-
etate (Table 1), likely because of its rapid metabolism in
the liver. BHB labeled with
13C at C4 and C2 would
contribute to
13C-labeling of glutamate-C4, as well as other
carbon positions. At euglycemia (control and 3dRH),
plasma BHB levels were low (
0.3 mmol/l), such that
labeling of glutamate-C4 would be negligible. However,
during hypoglycemia, baseline BHB levels were elevated
(
1 mmol/l) because animals were fasted overnight to
reduce their liver glycogen content. The lower rate of
brain glucose utilization in hypoglycemic 3dRH animals is
not likely attributable to increased consumption of ketone
bodies. BHB levels were the same in both groups, and
brain levels were not detected, implying similar blood-to-
brain concentration gradients—the driving force for BHB
utilization in the brain. Furthermore, if BHB utilization had
been greater in 3dRH compared with control animals,
there would have been greater dilution of brain gluta-
mate-C4 enrichment relative to control animals, which
was not seen (14.3 vs. 13.9%, P  0.14) (Table 2).
The contribution of acetate to astroglial TCA cycle ﬂux
(CMRac/VtcaA) under hypoglycemia was increased by 50%
in both control and 3dRH animals compared with eugly-
cemia. A similar value for the ratio CMRac/VtcaA was
reached in both groups (0.71  0.19 and 0.67  0.26 for
control and 3dRH, respectively), suggesting that acetate
metabolism was saturated in each case. This value is very
similar to the maximal value predicted for CMRac/VtcaA in
human subjects with type 1 diabetes (0.69  0.17) (13).
Assuming that our rat model of recurrent hypoglycemia
mimics relevant features of glial metabolism in humans,
the difference noted previously between type 1 diabetic
and control subjects are likely related to an increase in
transporter activity.
It is possible that reduced neuronal TCA cycle activity in
the context of preserved glycolytic ﬂux may have caused
the elevated lactate levels we observed in the brains of
3dRH animals under hypoglycemia. This lactate was less
enriched and could have been either derived from endog-
enous brain glycogen stores or derived directly from
unlabeled brain glucose. However, because our model
does account for labeled as well as unlabeled lactate as a
contribution to neuronal PDH ﬂux and the ﬁnal labeled
glutamate and glutamine pools were comparable, these
possibilities are not likely explanations for the signiﬁcant
decrease in VpdhN we observed.
3dRH animals showed higher GABA levels during acute
hypoglycemia, which was not observed in control animals
(Table 2). Other studies from our group have, in fact,
demonstrated a threefold increase in GABA in hypotha-
lamic interstitial ﬂuid (31) and increased long-term poten-
tiation in hippocampal slice preparations in rats exposed
to recurrent hypoglycemia (32). Because GABA is an
inhibitory neurotransmitter and increased levels could
reduce neuronal activity as well as metabolic demand
under hypoglycemic conditions in 3dRH animals, this
could be a cause of the reduced neuronal TCA cycle
activity we observed in our study.
In summary, our study provides the ﬁrst evidence that
recurrent hypoglycemia increases neuronal glucose me-
tabolism under euglycemia. Under hypoglycemia, glucose
metabolism decreased, whereas acetate utilization re-
mained constant, the latter supporting a greater relative
fraction of total oxidative metabolism. Neuron-speciﬁc
alternate fuels may therefore provide a means of reducing
the risk of hypoglycemia-induced brain injury in inten-
sively treated diabetic patients.
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